Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Strober

Showing results (51-60 of 130) with videos related to

Pageof 13
Sort By:
The American Journal of Medicine|August 24, 2014
Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbiditiesJulia Shlyankevich, Nehal N Mehta, James G Krueger, et al.
Dermatology and Therapy|February 27, 2021
Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry DermatologistsBruce Strober, Nirali Kotowsky, Rose Medeiros, et al.
Drugs - Real World Outcomes|June 24, 2024
Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis RegistryMark Lebwohl, Bruce Strober, Amy Schrader, et al.
Advances in Therapy|September 22, 2023
The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records DatabasesDarmendra Ramcharran, Bruce Strober, Kenneth Gordon, et al.
Journal of the American Academy of Dermatology|May 14, 2023
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trialBruce Strober, Carle Paul, Andrew Blauvelt, et al.
Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and ActivitiesAndrew Blauvelt, George C Gondo, Stacie Bell, et al.
Journal of the American Academy of Dermatology|September 22, 2023
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis RegistryBruce Strober, Laura Ferris, Kristina Callis Duffin, et al.
The British Journal of Dermatology|July 6, 2022
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)Andrew Blauvelt, Alexa B Kimball, Matthias Augustin, et al.
Journal of the American Academy of Dermatology|January 15, 2017
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanerceptBruce Strober, Alice B Gottlieb, Bintu Sherif, et al.
Journal of the American Academy of Dermatology|March 15, 2017
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III studyKim Papp, Herve Bachelez, Antonio Costanzo, et al.
Pageof 13

Showing results (51-60 of 130) with videos related to

Sort By:
Pageof 13
The American Journal of Medicine|August 24, 2014
Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbiditiesJulia Shlyankevich, Nehal N Mehta, James G Krueger, et al.
Dermatology and Therapy|February 27, 2021
Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry DermatologistsBruce Strober, Nirali Kotowsky, Rose Medeiros, et al.
Drugs - Real World Outcomes|June 24, 2024
Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis RegistryMark Lebwohl, Bruce Strober, Amy Schrader, et al.
Advances in Therapy|September 22, 2023
The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records DatabasesDarmendra Ramcharran, Bruce Strober, Kenneth Gordon, et al.
Journal of the American Academy of Dermatology|May 14, 2023
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trialBruce Strober, Carle Paul, Andrew Blauvelt, et al.
Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and ActivitiesAndrew Blauvelt, George C Gondo, Stacie Bell, et al.
Journal of the American Academy of Dermatology|September 22, 2023
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis RegistryBruce Strober, Laura Ferris, Kristina Callis Duffin, et al.
The British Journal of Dermatology|July 6, 2022
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)Andrew Blauvelt, Alexa B Kimball, Matthias Augustin, et al.
Journal of the American Academy of Dermatology|January 15, 2017
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanerceptBruce Strober, Alice B Gottlieb, Bintu Sherif, et al.
Journal of the American Academy of Dermatology|March 15, 2017
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III studyKim Papp, Herve Bachelez, Antonio Costanzo, et al.
Pageof 13